{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:57:48Z","timestamp":1763348268897},"reference-count":1,"publisher":"Oxford University Press (OUP)","issue":"S1","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:p>In the phase I ALPHA trial, the first allogeneic \u201coff-the-shelf\u201d CAR T-cell therapy regimen showed clinical benefits in patients with relapsed\/refractory large B-cell or follicular lymphoma.<\/jats:p>","DOI":"10.1634\/theoncologist.2020-0570","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T07:56:43Z","timestamp":1593244603000},"page":"S4-S5","source":"Crossref","is-referenced-by-count":2,"title":["First Allogeneic CAR T-Cell Therapy Impresses in Relapsed\/Refractory Lymphoma"],"prefix":"10.1093","volume":"25","member":"286","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"2021122511434808800_onco13431-bib-0001","author":"Neelapu","year":"2020"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2020-0570","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2020-0570","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2020-0570","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/S1\/S4\/41923067\/oncolo_25_s1_s4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/S1\/S4\/41923067\/oncolo_25_s1_s4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:43:52Z","timestamp":1640432632000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/S1\/S4\/6443574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":1,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2020,6,26]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2020-0570","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7,1]]},"published":{"date-parts":[[2020,6,26]]}}}